Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Discovery of short-course antiwolbachial quinazolines for elimination of filarial worm infections.

Bakowski MA, Shiroodi RK, Liu R, Olejniczak J, Yang B, Gagaring K, Guo H, White PM, Chappell L, Debec A, Landmann F, Dubben B, Lenz F, Struever D, Ehrens A, Frohberger SJ, Sjoberg H, Pionnier N, Murphy E, Archer J, Steven A, Chunda VC, Fombad FF, Chounna PW, Njouendou AJ, Metuge HM, Ndzeshang BL, Gandjui NV, Akumtoh DN, Kwenti TDB, Woods AK, Joseph SB, Hull MV, Xiong W, Kuhen KL, Taylor MJ, Wanji S, Turner JD, Hübner MP, Hoerauf A, Chatterjee AK, Roland J, Tremblay MS, Schultz PG, Sullivan W, Chu XJ, Petrassi HM, McNamara CW.

Sci Transl Med. 2019 May 8;11(491). pii: eaav3523. doi: 10.1126/scitranslmed.aav3523.

PMID:
31068442
2.

The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis.

Janes J, Young ME, Chen E, Rogers NH, Burgstaller-Muehlbacher S, Hughes LD, Love MS, Hull MV, Kuhen KL, Woods AK, Joseph SB, Petrassi HM, McNamara CW, Tremblay MS, Su AI, Schultz PG, Chatterjee AK.

Proc Natl Acad Sci U S A. 2018 Oct 16;115(42):10750-10755. doi: 10.1073/pnas.1810137115. Epub 2018 Oct 3.

3.

Lead optimization of imidazopyrazines: a new class of antimalarial with activity on Plasmodium liver stages.

Zou B, Nagle A, Chatterjee AK, Leong SY, Tan LJ, Sim WL, Mishra P, Guntapalli P, Tully DC, Lakshminarayana SB, Lim CS, Tan YC, Abas SN, Bodenreider C, Kuhen KL, Gagaring K, Borboa R, Chang J, Li C, Hollenbeck T, Tuntland T, Zeeman AM, Kocken CH, McNamara C, Kato N, Winzeler EA, Yeung BK, Diagana TT, Smith PW, Roland J.

ACS Med Chem Lett. 2014 Jul 6;5(8):947-50. doi: 10.1021/ml500244m. eCollection 2014 Aug 14.

4.

KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission.

Kuhen KL, Chatterjee AK, Rottmann M, Gagaring K, Borboa R, Buenviaje J, Chen Z, Francek C, Wu T, Nagle A, Barnes SW, Plouffe D, Lee MC, Fidock DA, Graumans W, van de Vegte-Bolmer M, van Gemert GJ, Wirjanata G, Sebayang B, Marfurt J, Russell B, Suwanarusk R, Price RN, Nosten F, Tungtaeng A, Gettayacamin M, Sattabongkot J, Taylor J, Walker JR, Tully D, Patra KP, Flannery EL, Vinetz JM, Renia L, Sauerwein RW, Winzeler EA, Glynne RJ, Diagana TT.

Antimicrob Agents Chemother. 2014 Sep;58(9):5060-7. doi: 10.1128/AAC.02727-13. Epub 2014 Jun 9.

5.

Targeting Plasmodium PI(4)K to eliminate malaria.

McNamara CW, Lee MC, Lim CS, Lim SH, Roland J, Simon O, Yeung BK, Chatterjee AK, McCormack SL, Manary MJ, Zeeman AM, Dechering KJ, Kumar TS, Henrich PP, Gagaring K, Ibanez M, Kato N, Kuhen KL, Fischli C, Nagle A, Rottmann M, Plouffe DM, Bursulaya B, Meister S, Rameh L, Trappe J, Haasen D, Timmerman M, Sauerwein RW, Suwanarusk R, Russell B, Renia L, Nosten F, Tully DC, Kocken CH, Glynne RJ, Bodenreider C, Fidock DA, Diagana TT, Winzeler EA.

Nature. 2013 Dec 12;504(7479):248-253. doi: 10.1038/nature12782. Epub 2013 Nov 27.

6.

Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.

Meister S, Plouffe DM, Kuhen KL, Bonamy GM, Wu T, Barnes SW, Bopp SE, Borboa R, Bright AT, Che J, Cohen S, Dharia NV, Gagaring K, Gettayacamin M, Gordon P, Groessl T, Kato N, Lee MC, McNamara CW, Fidock DA, Nagle A, Nam TG, Richmond W, Roland J, Rottmann M, Zhou B, Froissard P, Glynne RJ, Mazier D, Sattabongkot J, Schultz PG, Tuntland T, Walker JR, Zhou Y, Chatterjee A, Diagana TT, Winzeler EA.

Science. 2011 Dec 9;334(6061):1372-7. doi: 10.1126/science.1211936. Epub 2011 Nov 17.

7.

Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds.

Crowther GJ, Napuli AJ, Gilligan JH, Gagaring K, Borboa R, Francek C, Chen Z, Dagostino EF, Stockmyer JB, Wang Y, Rodenbough PP, Castaneda LJ, Leibly DJ, Bhandari J, Gelb MH, Brinker A, Engels IH, Taylor J, Chatterjee AK, Fantauzzi P, Glynne RJ, Van Voorhis WC, Kuhen KL.

Mol Biochem Parasitol. 2011 Jan;175(1):21-9. doi: 10.1016/j.molbiopara.2010.08.005. Epub 2010 Sep 15.

8.

Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication.

König R, Zhou Y, Elleder D, Diamond TL, Bonamy GM, Irelan JT, Chiang CY, Tu BP, De Jesus PD, Lilley CE, Seidel S, Opaluch AM, Caldwell JS, Weitzman MD, Kuhen KL, Bandyopadhyay S, Ideker T, Orth AP, Miraglia LJ, Bushman FD, Young JA, Chanda SK.

Cell. 2008 Oct 3;135(1):49-60. doi: 10.1016/j.cell.2008.07.032.

9.

Identification of novel therapeutic targets for HIV infection through functional genomic cDNA screening.

Nguyen DG, Yin H, Zhou Y, Wolff KC, Kuhen KL, Caldwell JS.

Virology. 2007 May 25;362(1):16-25. Epub 2007 Jan 25.

10.

4-Aminopyrimidines as novel HIV-1 inhibitors.

Gadhachanda VR, Wu B, Wang Z, Kuhen KL, Caldwell J, Zondler H, Walter H, Havenhand M, He Y.

Bioorg Med Chem Lett. 2007 Jan 1;17(1):260-5. Epub 2006 Oct 10.

PMID:
17035019
11.

Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.

Ellis D, Kuhen KL, Anaclerio B, Wu B, Wolff K, Yin H, Bursulaya B, Caldwell J, Karanewsky D, He Y.

Bioorg Med Chem Lett. 2006 Aug 15;16(16):4246-51. Epub 2006 Jun 16.

PMID:
16782337
12.

Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.

Wang Z, Wu B, Kuhen KL, Bursulaya B, Nguyen TN, Nguyen DG, He Y.

Bioorg Med Chem Lett. 2006 Aug 15;16(16):4174-7. Epub 2006 Jun 14.

PMID:
16781149
13.

Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.

Jiang T, Kuhen KL, Wolff K, Yin H, Bieza K, Caldwell J, Bursulaya B, Wu TY, He Y.

Bioorg Med Chem Lett. 2006 Apr 15;16(8):2105-8. Epub 2006 Feb 9.

PMID:
16480865
14.

Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.

Jiang T, Kuhen KL, Wolff K, Yin H, Bieza K, Caldwell J, Bursulaya B, Tuntland T, Zhang K, Karanewsky D, He Y.

Bioorg Med Chem Lett. 2006 Apr 15;16(8):2109-12. Epub 2006 Feb 7.

PMID:
16464578
16.

Generation of dendritic cells from lentiviral vector-transduced CD34+ cells from HIV+ donors.

Gruber A, Chen I, Kuhen KL, Wheat JC, Law P, Wong-Staal F.

J Med Virol. 2003 Jun;70(2):183-6.

PMID:
12696103
17.

Differential effects of HIV-1 protease inhibitors on dendritic cell immunophenotype and function.

Gruber A, Wheat JC, Kuhen KL, Looney DJ, Wong-Staal F.

J Biol Chem. 2001 Dec 21;276(51):47840-3. Epub 2001 Oct 15.

19.

Lentivirus replication and regulation.

Tang H, Kuhen KL, Wong-Staal F.

Annu Rev Genet. 1999;33:133-70. Review.

PMID:
10690406
23.

The PKR protein kinase--an interferon-inducible regulator of cell growth and differentiation.

Samuel CE, Kuhen KL, George CX, Ortega LG, Rende-Fournier R, Tanaka H.

Int J Hematol. 1997 Apr;65(3):227-37. Review.

PMID:
9114594
26.

Structural organization of the human gene (PKR) encoding an interferon-inducible RNA-dependent protein kinase (PKR) and differences from its mouse homolog.

Kuhen KL, Shen X, Carlisle ER, Richardson AL, Weier HU, Tanaka H, Samuel CE.

Genomics. 1996 Aug 15;36(1):197-201.

PMID:
8812437

Supplemental Content

Loading ...
Support Center